Índice de contenidos
  1. OJETIVOS DOCENTES DEL MÓDULO 4
  2. 1. INTERACCIONES CLÍNICAMENTE SIGNIFICATIVAS
  3. 2. MECANISMOS IMPLICADOS EN LAS INTERACCIONES FARMACOLÓGICAS EN ONCOLOGÍA
    1. 2.1. Interacciones farmacéuticas
    2. 2.2. Interacciones farmacodinámicas
    3. 2.3. Interacciones farmacocinéticas
      1. 2.3.1. Citocromo P 450
      2. 2.3.2. Papel de la glicoproteína-P (gp-P)
      3. 2.3.3. Receptores nucleares
  4. 3. INTERACCIONES QUE AFECTAN A LOS FÁRMACOS ANTINEOPLÁSICOS
    1. 3.1. Antimetabolitos análogos de pirimidinas
    2. 3.2. Inhibidores de la topoisomerasa I
    3. 3.3. Antimetabolitos análogos del ácido fólico
    4. 3.4. Taxanos
    5. 3.5. Antibióticos citostáticos: antraciclinas
    6. 3.6. Complejos de de platino
    7. 3.7. Epipodofilotoxinas
    8. 3.8. Mostazas nitrogenadas
    9. 3.9. Inhibidores de la protein-quinasa
    10. 3.10. Antagonistas de estrógenos
  5. 4. INTERACCIONES QUE AFECTAN A LA MEDICACIÓN DE SOPORTE
    1. 4.1. Anticoagulantes
    2. 4.2. Antieméticos
    3. 4.3. Hipolipemiantes
    4. 4.4. Analgésicos
    5. 4.5. Factores de desarrollo hematopoyético
    6. 4.6. Antibióticos, antifúngicos y antivirales
  6. 5.INTERACCIONES CON PLANTAS MEDICINALES
  7. 6. INTERACCIONES FÁRMACO-ALIMENTO
  8. 7. BIBLIOGRAFÍA
Descargar curso en PDF
Módulo 4
Profesor
Azucena Aldaz Pastor
Begoña Porta Oltra
Módulo 4 Acceso a Medinteract.net                                   
◄ anterior

7. BIBLIOGRAFÍA

  1. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can the be minimized?. Critical Reviews in Oncology/Hematology 2005; 55:117-142.
  2. Liu WM. Enhacing the cytotoxic activity of novel targeted therapies-is there a role for a combinatorial approach?. Curr Clin Pharmacol. 2008; 3(2): 108-17.
  3. Milano G, Spano JP, Leyland-Jones B. EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer 2008; 99: 1-5.
  4. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687–710.
  5. Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008; 47 (10): 669-680.
  6. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001; 40: 159-168.
  7. Harmsen S, Meijerman I, Beijnen JH, Schellens JHM. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treatment Reviews 2007; 33: 369-380.
  8. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004; 24: 1508-14
  9. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94:1247-9.
  10. Kanamitsu SI, Ito K, Okuda H et al. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2bromovinyl)uracil. Drug metab Dispos 2000; 28:467-74.
  11. Vetch CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet neurology. 2003; 2: 404-409.
  12. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006; 6(/):546-58.
  13. Baena-Cañada JM, Martínez MJ, García-Olmedo O, Jiménez-Bárcenas R, Muriel-Cueto P. Interaction between capecitabine and brivudin in a patient with breast cancer. Nat Rev Clin Oncol. 2010;6:55-58.
  14. De Jong JA, van der Bol JM, Mathijssen RH, Loos WJ, Mathôt RA, Kitzen JJ, et al. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatoxicity. Cancer Biol Ther 2007; 6 (9): 1368-74.
  15. Armijo JA, Sánchez MB, Campos C, Adín J. The interactions of antiepileptic drugs in oncology practice Rev Neurol. 2006; 42(11):681-90.
  16. Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL et al. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Clinical Therapeutics 2005; 27 (3): 327-335.
  17. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992;26(2):234-7.
  18. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther. 2004 Apr;309(1):226-34.
  19. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44-9.
  20. Beijnen JH, Schellens JHM. Drug interactions in oncology. Lancet Oncol 2004; 5: 489-96.
  21. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy Clin Pharmacokinet. 2005;44(2):111-45.
  22. Kruijtzer CMF, Beijnen JH, et al. Weekly oral paclitaxel as first-line treatment in patients with advanced cancer. Ann Oncol 2003; 14: 197-204.
  23. Liu J, Lee H, Allen C. Formulation of drugs in block copolymer micelles: drug loading and release Curr Pharm Des. 2006;12(36):4685-701.
  24. Venturini M, Lunardi G, Mastro L, et al: Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 2000; 18(10):2116-2125.
  25. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol 2001; 28(4suppl 12): 15-23
  26. Elkiran T, Harputluoglu H, Yasar U, Babaoglu MO, et al. Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients. Methods Find Exp Clin Pharmacol 2007; 29(1): 27-32.
  27. Zucchero FJ, Morgan MJ, Sommer CD. Evaluations of drug interactions. St. Louis, MO. First DataBank; 2001.
  28. Hilkens PHE, Pronk LC, Verweij J, et al: Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997; 75:417-422.
  29. Wang H, Li M, Rinchart JJ, Zhang R. Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol. 2004; 53: 459-467.
  30. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2003; 2 (7): 404-9.
  31. Scripture CD, Sparreboom A, Figg WF. Modulation of citochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005; 6:780-789.
  32. Rochat B. Role of cytochrome P-450 activity in the fate of anticancer agents and in drug resistance. Focus on tamoxifen, paclitaxel and imatinib matabolism. Clin Pharmacokinet 2005; 44(4) 349-366.
  33. Dutreix C, Peng B, Mehring G, et al: Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.. Cancer Chemother Pharmacol 2004; 54: 290-294.
  34. Swaisland H, Smith RP, Farebrother J, Laight A. The effect of the induction and inhibition of CYP3A4 on the pharmacokinetics of single oral doses of ZD1839 (“Iressa”), a selective epidermal growth factor receptor tyrosine kinasa inhibitor (EGFR-TKI), in healthy male volunteers. Proc Am Soc Clin Oncol 2002; 21 (abstract 328).
  35. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Ins 2003; 95: 1758-64.
  36. Yap KYL., Tay WL, Chui WK, Chan A. Clinically relevant drug interactions between anticancer drugs and psychotropic agents European Journal of Cancer Care 2011; 20, 6–32.
  37. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al.. CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. J Natl Cancer Ins 2005; 1 (97): 30-39.
  38. Wasif Saif M, Wasif N. Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer. JOP. J Pancreas (online). 2008;9(6):739-43 (http://www.joplink.net)
  39. Thomas KS, Billingsley A, Amarshi N, Nair BA. Elevated international normalized ratio associated with concomitant warfarina and erlotinib. Am J Health Pharm. 2010;67(17):1426-1439.
  40. Cagnoni PJ, Matthes S, Day TC, et al: Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999; 24:1-4.
  41. de Jonge ME, Huitema ADR, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56:370-78.
  42. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatina. Clinical Lung Cancer. 2008; 4(9):232-234.
  43. de Wit R, Verweij J, Bontenbal M et al. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst 1996; 14:935-40.
  44. Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDs-related Kaposi’s sacoma. AIDS 1999;13:283-284.
  45. Sparreboom A, Cox MC, Achayra MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22: 2489-2503
  46. Tascilar M, de Jong FA, Verweij J et al. Complementary and alternative medicine during cancer treatment: beyond innocence. The Oncologist 2006; 11:732-741.
  47. Meijerman I, Beijnen JH, Schellens JHM. Herb-Drug interactions in Oncology: focus on mechanisms of induction. The Oncologist 2006; 11:11:742-752
  48. Van Cutsem E, Hoff PM; Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluoruracil and leucovorin: integrated efficacy data and novel analices from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-1197. 
  49. Goodin S. Oral chemotherapy agents: understanding mechanism of action and drug interactions. Am J Health Syst Pharm 2007; 64 (9 Suppl 5): S15-24.
  50. Guidance for Industry. Drug interaction studies-study design, data analysis, and implications for doping and labelling (Draft Guidance). USA. FDA. September, 2006. Clinical Pharmacology.
  51. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T. Single-Dose clinical pharmacokinetic studies of Gefitinib. Clin Pharmacokinet 2005; 44 (11): 1165-1177.
  52. Santos CA, Boullata JI. An approach to evaluating drug-nutrient interactions. Pharmacotherapy 2005; 25 (12): 1789-1800.
  53. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer drugs. Underlying mechanism and implications for oral chemotherapy. Clin Pharmacokinet 2004; 43: 15: 1127-1156.